Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
Status:
Terminated
Trial end date:
2017-06-03
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if pacritinib, either alone or in
combination with azacitidine or decitabine, can help to control MDS.
The safety of this drug and drug combination will also be studied.